{"id":"gsk-investigational-vaccine-gsk2340272a","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vaccine candidate, GSK2340272A works by presenting antigens to the immune system to generate both humoral (antibody) and cellular (T-cell) immune responses. The vaccine formulation likely includes adjuvants or delivery systems to enhance immunogenicity and protective immunity against its target pathogen or disease.","oneSentence":"GSK2340272A is an investigational vaccine designed to stimulate immune responses against specific disease targets through antigen presentation and T-cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:38.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00968539","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":130},{"nctId":"NCT00989287","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-07","conditions":"Influenza","enrollment":131},{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00968526","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":240},{"nctId":"NCT00975884","phase":"PHASE3","title":"Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-14","conditions":"Influenza","enrollment":312},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT00992511","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-14","conditions":"Influenza","enrollment":300},{"nctId":"NCT00989612","phase":"PHASE2","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT00951041","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-11","conditions":"Influenza","enrollment":130},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT00979407","phase":"PHASE3","title":"Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Influenza","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK investigational vaccine GSK2340272A","genericName":"GSK investigational vaccine GSK2340272A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":6},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}